Most interestingly, we identified that knockdown of JMJD6 (Jumonji Domain Containing 6, Arginine Demethylase and Lysine Hydroxylase) significantly increased both Aβ42 to 40 and p231-tau to tau ratios, suggesting therapeutic relevance to multiple stages of AD pathology. The gene discussed is JMJD6; the disease is Alzheimer disease.